Aktienanalyse zu Trinity Biotech PLC (TRIB)TRIBTrinity Biotech PLC

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV. It operates in the Healthcare sector.

Trinity Biotech PLC (TRIB) is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $6.07, and the stock has a very low RSI of 23.25, indicating it is oversold. Furthermore, the forward P/E ratio is 4.54, which might seem attractive, but the company has a negative net income of -$4.39 million in Q1 2026 and a gross margin of only 35.43%. The main risk is the company's failure to regain Nasdaq compliance, which could further depress the stock price.

3 analysts cover TRIB: 3 rate it Buy, 0 Hold and 0 Sell.